Form 4: RxSight Executive Ilya Goldshleger Executes Stock Option and Sells Shares

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock between October 16 and October 18, 2024, according to a recent SEC filing.

Summary

• Ilya Goldshleger, Co-President and COO of RxSight, Inc., filed a Form 4 with the SEC detailing changes in beneficial ownership.
• On October 16, 2024, Goldshleger exercised options to acquire 3,100 shares of common stock at a price of $15.08 per share and sold 3,100 shares at a weighted average price of $49.7799.
• On October 18, 2024, Goldshleger exercised options to acquire 3,105 shares of common stock at a price of $15.08 per share and sold 3,075 shares in multiple transactions at prices ranging from $50.0745 to $50.59.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 3, 2024.
• Following these transactions, Goldshleger directly owns 42,246 shares of common stock and indirectly owns 1,372 shares through a spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider trading activity. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider trading activity and doesn't necessarily indicate a broader trend within the ophthalmic industry. However, monitoring insider transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the reported transactions appear to be within the normal course of business.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information.
• Comparable companies in the medical device sector, such as STAAR Surgical or Glaukos, also have executives who periodically exercise stock options and sell shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, so the impact on stakeholders is expected to be limited.

Key Dates